- Home
- REPL vs ANL Comparison
REPL vs ANL Comparison
Compare REPL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REPL | ANL |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.8M | 703.3M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | REPL | ANL |
|---|---|---|
| Price | $1.96 | $16.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $5.67 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 7.3M | 555.9K |
| Earning Date | 05-21-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.88 |
| 52 Week High | $13.24 | $17.04 |
Technical Indicators
Market Signals| Indicator | REPL | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 23.87 | 69.31 |
| Support Level | $1.50 | $1.36 |
| Resistance Level | $8.82 | N/A |
| Average True Range (ATR) | 0.75 | 2.43 |
| MACD | -0.42 | 0.65 |
| Stochastic Oscillator | 6.05 | 86.44 |
Price Performance
Historical ComparisonAbout REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.